Currently, there are (7) active studies within Columbia University Medical Center:

A Two Part Seamless, Open-label, Multicenter Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of RO7034067 in Infants With Type 1 Spinal Muscular Atrophy (Firefish)

Open-label, multi-center clinical study is to assess the safety, tolerability, pharmacokinetic, pharmacodynamics, and efficacy of RO7034067 in infants with Type 1 spinal muscular atrophy (SMA). The study consists of two parts, an exploratory dose finding part (Part 1) and a confirmatory part (Part 2) which will investigate RO7034067 for 24-months at the dose selected in Part 1.

Ages Eligible for Study: 1 Month to 7 Months (Child)
Sexes Eligible for Study: All
Accepts Healthy Volunteers: No

Inclusion Criteria:
• Clinical history, signs or symptoms attributable to Type 1 SMA with onset after 28 days but prior to the age of 3 months
• Gestational age of 37 to 42 weeks
• Confirmed diagnosis of 5q-autosomal recessive SMA
• Participants has two survival motor neuron 2 (SMN2) gene copies, as confirmed by central testing
• Body weight greater than or equal to (>=) third percentile for age, using appropriate country-specific guidelines
• Receiving adequate nutrition and hydration (with or without gastrostomy) at the time of screening, in the opinion of the Investigator
• Adequately recovered from any acute illness at the time of screening and considered well-enough to participate in the opinion of the Investigator

Exclusion Criteria:
• Concomitant or previous participation in any investigational drug or device study within 90 days prior to screening or 5 half-lives, whichever is longer
• Concomitant or previous participation in a SMN2 targeting antisense oligonucleotide or SMN2 splicing modifier or gene therapy study
• Any history of cell therapy
• Hospitalization for pulmonary event within the last 2 months, or planned at the time of screening
• Presence of clinically relevant electrocardiogram (ECG) abnormalities before study drug administration
• Unstable gastrointestinal, renal, hepatic, endocrine or cardiovascular system diseases
• Participants requiring invasive ventilation or tracheostomy
• Participants requiring awake non-invasive ventilation or with awake hypoxemia (arterial oxygen saturation less than [<] 95 percent [%]) with or without ventilator support
• Participants with a history of respiratory failure or severe pneumonia, and have not fully recovered their pulmonary function at the time of screening
• Multiple or fixed contractures and/or hip subluxation or dislocation at birth
• Presence of non-SMA related concurrent syndromes or diseases
• Any major illness within one month before the screening examination or any febrile illness within one week prior to screening and up to first dose administration
• Any inhibitor of cytochrome P450 (CYP) 3A4 and/or any Organic Cation Transporter 2 (OCT-2) and multidrug and toxin extrusion (MATE) substrates taken within 2 weeks and/or any inducer of CYP3A4 taken within 4 weeks (or within 5-times the elimination half-life, whichever is longer) prior to dosing or participants (and the mother, if breastfeeding the infant) taking any nutrients known to modulate CYP3A activity and any known flavin containing monooxygenase (FMO) 1 or FMO3 inhibitors or substrates
• Prior use, anticipated need for hydroxychloroquine, vigabatrin, retigabine, or any other drug known to cause retinal toxicity during the study
• Recent history (less than 6 months) of ophthalmic disease that would interfere with the conduct of the study as assessed by an ophthalmologist

Estimated Enrollment: 48
Actual Study Start Date: December 23, 2016
Estimated Study Completion Date: July 7, 2020

Additional participating locations:
**Domestic: Stanford** University Medical Center (California)

**International:** UZ Gent (Belgium), UZ Leuven Gasthuisberg (Belgium), Hospital Arman Trousseau (France), Policlinico Agostino Gemelli; Dipartimento di Neurosichiatria Infantile (Italy), Fonadazione IRCCS Istituto Neurologico “Carla Besta”; UO di Neurologia dello Sviluppo (Italy), Universitats-Kinderspitalbeider Basel_Abteilung fur Neuro-und Entwicklungspadiatrie (Switzerland), Hacettepe University (Turkey)

If you would like more information about this study please contact Claudia Chiriboga, MD, MPh or Luz Sanabria at ls2328@cumc.columbia.org